Korea turns a deaf ear to industry calls for simpler stem cell clinical requirement
This article was originally published in Clinica
Executive Summary
South Korea’s Ministry of Food and Drug Safety has rejected industry demands to simplify the process for collecting information on the safety and efficacy of stem cell therapies during clinical usage. From July, stem cell therapy companies will be obliged to conduct complete surveys on all patients who receive the therapies.